|1.||Willick, G E: 2 articles (02/2001 - 04/2000)|
|2.||Barbier, J R: 2 articles (02/2001 - 04/2000)|
|3.||Isaacs, R J: 2 articles (02/2001 - 04/2000)|
|4.||Morley, P: 2 articles (02/2001 - 04/2000)|
|5.||MacLean, S: 2 articles (02/2001 - 04/2000)|
|6.||Ross, V: 2 articles (02/2001 - 04/2000)|
|7.||Whitfield, J F: 2 articles (02/2001 - 04/2000)|
|8.||Andreassen, T T: 1 article (02/2001)|
|9.||Holdsworth, D W: 1 article (04/2000)|
|10.||Watson, P H: 1 article (04/2000)|
|1.||Body Weight (Weight, Body)
04/01/2000 - "Here we show that when injected once daily for 6 weeks starting 2 weeks after OVX in doses of 1 or 2 nmol/100 g of body weight, hPTH-(1-31)NH2, [Leu27] cyclo(Glu22-Lys26)hPTH-(1-31)NH2, and hPTH-(1-34)NH2 prevented the loss of trabecular volume in the L5 vertebrae induced by OVX. "
01/01/1997 - "Thus daily subcutaneous injections of 0.6 nmol/100 g of body weight of rhPTH-(1-84) or hPTH-(1-31)NH2 into 3-month-old OVX rats for 6 weeks starting 2 weeks after OVX equally reduced the otherwise large OVX-triggered loss of femoral trabecular bone. "
11/01/1998 - "hPTH-(1-31)NH2, so far the smallest of the potently anabolic N-terminal fragments of the human parathyroid hormone, stimulates trabecular growth in the distal femurs of ovariectomized (OVX) rats as strongly as hPTH-(1-34) when injected at a high daily dose such as 1 nmol/100 g of body weight, but it is only about 70% as effective as hPTH-(1-34) when injected at the suboptimal 0.6 nmol/100 g of body weight. "
02/01/1996 - "hPTH-(1-31)NH2 (which we have named Ostabolin) can greatly thicken trabeculae and increase the dry weight and calcium content of trabecular bone in the distal femurs of osteopenic, young, sexually mature OVX Sprague-Dawley rats when injected subcutaneously each day for 6 weeks at doses between 0.4 and 1.6 nmole/100 g of body weight."
|2.||Osteosarcoma (Osteogenic Sarcoma)
01/01/1997 - "A recombinant human parathyroid hormone, rhPTH-(1-84), which is currently in Phase II clinical trial, and hPTH-(1-31)NH2 (Ostabolin) are promising anabolic agents for treating osteoporosis because they can stimulate cortical and trabecular bone growth in osteopenic, ovariectomized (OVX) rats and in osteoporotic, postmenopausal women when injected subcutaneously and intermittently at low doses. "
|4.||Metabolic Bone Diseases (Osteopenia)
|1.||human parathyroid hormone (1-31)amide
|2.||Parathyroid Hormone (Parathormone)
|5.||Adenylate Cyclase (Adenylyl Cyclase)